Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

The purpose of this trial is to compare the evolution of patients receiving first line treatment for locally advanced or metastatic lung cancer, taking into account if they were requested or not the EGFR mutation test as part of the diagnosis and treatment strategy. There is no assignment to any particular therapeutic strategy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stage IIIB/IV Adenocarcinoma Adenocarcinoma of Lung Bronchial Neoplasms Carcinoma Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Non-small Cell Lung Cancer Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Bahía Blanca, Buenos Aires, Argentina

About this study

Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with confirmed diagnosis of lung adenocarcinoma, stage IIIb/IV.
Patients under 1st line treatment against lung adenocarcinoma.

Exclusion criteria

Patients not having the information required by the protocol.

Treatment and study plan

Primary outcomes

Disease free survival

Time frame: 12 months after the diagnosis of advanced disease
Overall Survival

Time frame: 12 months after the diagnosis of advanced disease
Number of hospitalizations

Time frame: 12 months after the diagnosis of advanced disease

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Study of Cases and Controls on Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.

Acronym: IDENTIFY

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2013
First posted: Feb 2, 2012
Registry last updated: Apr 14, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed